[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
American Society for Experimental Neurotherapeutics Abstracts
August 2001

Alzheimer Disease

Arch Neurol. 2001;58(8):1315. doi:

Alzheimer disease is the leading cause of dementia. The β-amyloid peptide, the core constituent of neuritic plaques found in the brain tissue of patients with the disease, has been identified as a possible causative agent in the pathophysiology of the disease. A variety of therapies are aimed at either reducing the production of this peptide (ie, β- or γ-secretase inhibitors) or improving its clearance from the brain. Recently, immunization with β-amyloid peptide proved remarkably effective in amyloid precursor protein transgenic mouse models of the disease in both preventing the occurrence of plaques and reducing existing pathologic findings in older animals. This immunotherapeutic effect of Aβ appears to be mediated by antibodies against the peptide. These findings have fostered efforts to test this strategy clinically for the possible treatment of Alzheimer disease.

×